60 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Article Searches
Down -63.39% in 4 Weeks, Here's Why Gritstone bio (GRTS) Looks Ripe for a Turnaround https://www.zacks.com/stock/news/2251859/down-63-39-in-4-weeks-here-s-why-gritstone-bio-grts-looks-ripe-for-a-turnaround?cid=CS-ZC-FT-tale_of_the_tape|rsi-2251859 Apr 08, 2024 - Gritstone bio (GRTS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Here's Why You Should Invest in Entera Bio (ENTX) Stock Now https://www.zacks.com/stock/news/2252481/here-s-why-you-should-invest-in-entera-bio-entx-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2252481 Apr 09, 2024 - Here, we discuss some reasons why buying Entera Bio (ENTX) stock now may turn out to be a prudent move.
Does Belite Bio (BLTE) Have the Potential to Rally 41.14% as Wall Street Analysts Expect? https://www.zacks.com/stock/news/2253383/does-belite-bio-blte-have-the-potential-to-rally-41-14-as-wall-street-analysts-expect?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2253383 Apr 10, 2024 - The consensus price target hints at a 41.1% upside potential for Belite Bio (BLTE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Jefferies cuts Instil Bio to hold, cites drug discontinuation https://seekingalpha.com/news/4089263-jefferies-cuts-instill-bio-to-hold-cites-drug-discontinuation?source=feed_sector_healthcare Apr 12, 2024 - Jefferies downgraded Instil Bio (TIL) to hold, citing discontinuation of clinical development for the company’s drug candidate ITIL-306.
Is Bluebird Bio Stock a Buy? https://www.fool.com/investing/2024/04/15/is-bluebird-bio-stock-a-buy/?source=iedfolrf0000001 Apr 15, 2024 - This small biotech is struggling to fly -- and investors should probably steer clear.
Mustang Bio stock tumbles 27% amid news of mass layoffs https://seekingalpha.com/news/4089763-mustang-bio-stock-tumbles-amid-news-of-mass-layoffs?source=feed_sector_healthcare Apr 15, 2024 - Mustang Bio (MBIO) stock tumbled 27% Monday in the wake of news that the company plans to cut around 81% of its workforce to conserve cash. Read more here.
Telesis Bio announces leadership transition amid new commercial focus https://seekingalpha.com/news/4091115-telesis-bio-stock-slips-amid-new-ceo?source=feed_sector_healthcare Apr 18, 2024 - Telesis Bio (TBIO) stock slipped as the company promoted its Chief Operating Officer Eric Esser to the CEO role. Read more here.
Zura Bio stock jumps on plans to raise $112.5M in private financing https://seekingalpha.com/news/4091083-zura-bio-stock-jumps-on-plans-to-raise-1125m-in-private-financing?source=feed_sector_healthcare Apr 18, 2024 - Zura Bio (ZURA) shares jumped around 12% after the immunology company entered into subscription agreements for a private placement.
Entera Bio Ltd. (ENTX) Stock Slides as Market Rises: Facts to Know Before You Trade https://www.zacks.com/stock/news/2263665/entera-bio-ltd-entx-stock-slides-as-market-rises-facts-to-know-before-you-trade?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2263665 Apr 26, 2024 - The latest trading day saw Entera Bio Ltd. (ENTX) settling at $1.98, representing a -1% change from its previous close.
Annovis Bio tumbles 53% on data for Alzheimer's candidate buntanetap https://seekingalpha.com/news/4095540-annovis-bio-alzheimers-tumbles-53-data-alzheimers-candidate-buntanetap?source=feed_sector_healthcare Apr 29, 2024 - Annovis Bio's Alzheimers disease candidate, buntanetap, triggers trading halts as shares fall ~53%, indicating potential disappointment in trial results. Read more here

Pages: 123456

<<<Page 6